Alkermes

ALKS

Market cap $7.03B

DUBLIN--(BUSINESS WIRE)--Alkermes plc (Nasdaq: ALKS) today announced plans to present clinical and real-world data related to the company's psychiatry and orexin portfolios at the American Society of Clinical Psychopharmacology Annual Meeting, taking place May 26-29, 2026 in Miami. The poster presentations include data related to Alkermes' proprietary commercial medicines, LYBALVI® (olanzapine and samidorphan) and ARISTADA® (aripiprazole lauroxil), and its pipeline of investigational orexin 2 r.

DUBLIN--(BUSINESS WIRE)--Alkermes plc (Nasdaq: ALKS) today announced the presentation of accepted research at key scientific conferences this spring related to its psychiatry products—LYBALVI® (olanzapine and samidorphan) and ARISTADA® (aripiprazole lauroxil)—and its ongoing involvement in sleep medicine. The data presented reflect Alkermes' ongoing commitment to contributing to the advancement of patient care and expanding the body of evidence in neuroscience. The meetings included: The Psych.

Alkermes Inc. plc (NASDAQ:ALKS) stock is trading higher on Tuesday following the announcement of positive topline results from the REVITALYZ phase 3 study evaluating LUMRYZ extended-release oral suspension for excessive daytime sleepiness associated with idiopathic hypersomnia.

DUBLIN--(BUSINESS WIRE)--Alkermes plc (Nasdaq: ALKS) today announced positive topline results from the REVITALYZ℠ double-blind, placebo-controlled, randomized withdrawal, multicenter phase 3 study evaluating the investigational use of LUMRYZ® (sodium oxybate) extended-release oral suspension in adults with idiopathic hypersomnia (IH). LUMRYZ met the study's primary endpoint, demonstrating statistically significant improvements in excessive daytime sleepiness compared to placebo as measured by t.

Alkermes (NASDAQ:ALKS) reported upbeat results for the first quarter on Tuesday.

ALKS beats Q1 estimates as strong proprietary drug sales lift revenues by 28%, sending shares higher, while Lumryz adds a fresh growth driver.

Alkermes is transitioning into an integrated neuroscience and sleep medicine company, highlighted by the Avadel acquisition and LUMRYZ integration. Q1 2026 results show proprietary product sales rising to $338.1M, with LUMRYZ contributing $39.5M post-acquisition; adjusted EBITDA improved to $80.3M. Management projects 2026 revenues of $1.73–$1.84B, with four commercial products each targeting over $300M in annual net sales.

Alkermes plc (ALKS) Q1 2026 Earnings Call Transcript

While the top- and bottom-line numbers for Alkermes (ALKS) give a sense of how the business performed in the quarter ended March 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Alkermes (ALKS) came out with a quarterly loss of $0.4 per share versus the Zacks Consensus Estimate of a loss of $0.57. This compares to earnings of $0.13 per share a year ago.